Innoviva Inkomsten in het verleden

Verleden criteriumcontroles 2/6

De winst van Innoviva is gedaald met een gemiddeld jaarlijks percentage van -12.5%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 1.2%. De inkomsten zijn groeide met een gemiddeld percentage van 1.8% per jaar. Het rendement op het eigen vermogen Innoviva bedraagt 9.7% en de nettomarge bedraagt 18.3%.

Belangrijke informatie

-12.5%

Groei van de winst

-1.5%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	1.8%
Rendement op eigen vermogen	9.7%
Nettomarge	18.3%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Recent updates

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

Opbrengsten en kosten

Hoe Innoviva geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:INVA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	353	65	111	-21
30 Jun 24	330	145	113	0
31 Mar 24	312	181	109	0
31 Dec 23	310	180	98	0
30 Sep 23	290	50	84	31
30 Jun 23	290	233	83	0
31 Mar 23	318	233	71	0
31 Dec 22	331	214	58	0
30 Sep 22	373	293	46	0
30 Jun 22	404	99	21	0
31 Mar 22	396	188	13	0
31 Dec 21	392	266	16	0
30 Sep 21	375	309	17	0
30 Jun 21	365	265	17	0
31 Mar 21	344	253	16	0
31 Dec 20	337	224	12	0
30 Sep 20	322	216	8	0
30 Jun 20	299	228	9	0
31 Mar 20	285	189	11	0
31 Dec 19	261	157	15	0
30 Sep 19	265	375	17	0
30 Jun 19	261	382	13	0
31 Mar 19	264	399	13	0
31 Dec 18	261	395	19	0
30 Sep 18	251	190	17	0
30 Jun 18	238	166	24	0
31 Mar 18	229	147	30	0
31 Dec 17	217	134	32	0
30 Sep 17	191	101	35	0
30 Jun 17	176	92	32	0
31 Mar 17	150	72	28	0
31 Dec 16	134	60	23	0
30 Sep 16	113	38	22	0
30 Jun 16	93	19	22	0
31 Mar 16	71	-4	21	0
31 Dec 15	54	-19	20	0
30 Sep 15	38	-39	21	0
30 Jun 15	26	-56	25	0
31 Mar 15	16	-68	29	0
31 Dec 14	8	-74	35	0
30 Sep 14	3	-66	35	0
30 Jun 14	2	-55	32	0
31 Mar 14	2	-9	27	0
31 Dec 13	5	-31	24	0

Kwaliteitswinsten: INVA heeft een grote eenmalige verlies van $98.4M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th September, 2024.

Groeiende winstmarge: De huidige netto winstmarges (18.3%) INVA } zijn hoger dan vorig jaar (17.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van INVA is de afgelopen 5 jaar met 12.5% per jaar gedaald.

Versnelling van de groei: De winstgroei van INVA over het afgelopen jaar ( 29.5% ) overtreft het 5-jarig gemiddelde ( -12.5% per jaar).

Winst versus industrie: De winstgroei INVA over het afgelopen jaar ( 29.5% ) overtrof de Pharmaceuticals -sector 54.6%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 9.7% ) van INVA wordt als laag beschouwd.

Innoviva Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Earnings quality

Price target increased by 20% to US$18.00

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Innoviva: Potentially Overvalued

Now 21% undervalued

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

New 90-day high: US$12.51

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Investor sentiment improved over the past week

New 90-day high: US$11.81

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP